Centre deploys three teams to manage high measles cases among children

The teams will assist the state health authorities in instituting public health measures and facilitate operationalization of requisite control and containment measures

SMS Pharma revenue down 9%

Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market

Voltas forays into the bio medical refrigeration and cold chain

Ties up with Denmark’s Vestfrost Solutions, to cater to the unique needs of the Indian market

Biocon Q2FY23 net profit slips 10% to Rs 168 Cr; Revenue up 26%

Chemcon Q2 FY23 revenue down 5.4%; Profit down 46.6%

Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers

Ayu Health receives US $27 million additional funding

The company is making its entry into the Hyderabad market through its unique asset-light business model

Rossari Biotech Q2 FY23 revenue up 11%; Profit down 9%

H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY

Sustaining growth momentum is key for Navin Fluorine: ICICI Securities

NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.

Camizestrant significantly improved PFS vs. Faslodex in SERENA-2 Phase II trial

Results reinforce commitment to next-generation oral SERD development programme

Laurus Labs planning Rs. 2,000 Cr Capex

On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions